

## THE CLINICAL RESEARCH PATH TOWARDS HIV CURE: FOCUS ON THE DIORR TRIAL

**Author:** McMahon JH<sup>1,2</sup>

<sup>1</sup>Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia

<sup>2</sup>Department of Infectious Diseases, Monash Medical Centre, Melbourne, Australia

An increasing number of clinical trials using interventions to target persistent HIV and/or understand how the HIV reservoir is maintained are being reported. Increasingly these studies are combining different types of interventions, including interruptions of antiretroviral therapy as a key study endpoint and describing some individuals who achieve periods of controlling viral replication longer than is typically expected when ceasing antiretroviral therapy. Highlights from recently reported clinical trials, and studies that are currently underway where results are keenly awaited will be reported. Another controversy in the field of HIV cure has been the potential for residual replication of HIV to maintain the reservoir. This question was further investigated with a randomized controlled trial of dolutegravir intensification that was recently completed in Australia (The DIORR trial). Results of this trial will also be presented and its implications for the field.

**Disclosure of Interest Statement:** JHMs institution has received funding for research from ViiV, Gilead and Merck Sharp & Dohme Corp.